-+ 0.00%
-+ 0.00%
-+ 0.00%

Schott Pharma FY26 Q3 EBITDA margin drops 2.1 percentage points to 26.8%; revenue rises 10% to EUR 281.8 million

PUBT·08/12/2026 05:02:05
Listen to the news
Schott Pharma FY26 Q3 EBITDA margin drops 2.1 percentage points to 26.8%; revenue rises 10% to EUR 281.8 million
  • Schott Pharma reported Q3 revenue up 10% to EUR 281.8 million, lifting 9M revenue 4.1% to EUR 769.8 million.
  • 9M EBITDA fell to EUR 205.3 million, pushing the EBITDA margin down 2.2 percentage points to 26.7%.
  • Free cash flow improved 49% to EUR 58.9 million in 9M, while 9M capex edged down to EUR 82.5 million.
  • DCS revenue rose 7.6% to EUR 445.4 million in 9M; DDS revenue slipped 0.2% to EUR 325.1 million.
  • Management flagged stronger demand for polymer syringes outside mRNA, confirmed FY2026 revenue growth of 5%-6% and EBITDA margin of 27%-28%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schott Pharma AG & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2380588_de) on August 12, 2026, and is solely responsible for the information contained therein.